Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Health
  • Nyse
  • Yacht Buyer
  • Banking
  • Stocks
  • Finance
ncarol.com

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
ncarol.com/10291348

Trending...
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
  • Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - ncarol.com -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on ncarol.com
  • Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers
  • Simpalm Staffing Services Launched its Refreshed Website for Remote Staffing Services
  • Claude Riveloux Review 2026: How the $10B Fund Manager Dispels 'Scam' Rumors Through Education
  • Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
  • Danholm Collection Launches Boutique Luxury Real Estate Brokerage in Central Florida

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
  • Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
  • Cancun International Airport Prepares for Record Travel Surge Ahead of Spring Break, Summer, and the 2026 High Season
  • $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
  • Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026
  • ADB Selects OneVizion to Advance Field Execution and Infrastructure Program Management
  • Memelinked Social Media powered by cryptocurrency launching July 2026
  • DwellSafe and Bruno Partner to Bring Clinician-Backed Stairlift Education to Families
  • Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
  • Leoforce Releases Beyond Programmatic: A Practical Guide to Long-Term Hiring Outcomes
  • Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
  • Spring Surge in 55+ Communities: What Buyers and Sellers Need to Know in 2026
  • Jason Caras Launches The Caras Institute Following Successful Exit from IT Authorities
  • Serina Damesworth Hired as Century Fasteners Corp. – Director of Quality
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Distributed Social Media - Own Your Content
  • Tarrytown Expocare Pharmacy Announces Strategic Leadership Appointments to Accelerate Growth and Innovation
  • New Environmental Thriller "The Star Thrower" Reimagines a Classic Lesson in Individual Impact
  • Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
  • Interview: Why I Sponsored Carson Ware - The Full Story
_catLbl0 _catLbl1

Popular on ncarol.com

  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies - 118
  • Still Using Ice? FrostSkin Reinvents Hydration - 103
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments - 102
  • Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Cold. Clean. Anywhere. Meet FrostSkin
  • High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)

Similar on ncarol.com

  • 13 Full Moons of Black Dandelion Convergent Voice™ An Integration of Literacy & Wellness Symposium
  • Yoga Retreats, Ecstatic Dance & Spiritual App launched
  • Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers
  • Williamsville Spa Expands Team to Meet Growing Demand for Professional Facials
  • Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
  • Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
  • $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
  • DwellSafe and Bruno Partner to Bring Clinician-Backed Stairlift Education to Families
  • Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute